JP2023532040A5 - - Google Patents

Info

Publication number
JP2023532040A5
JP2023532040A5 JP2022580236A JP2022580236A JP2023532040A5 JP 2023532040 A5 JP2023532040 A5 JP 2023532040A5 JP 2022580236 A JP2022580236 A JP 2022580236A JP 2022580236 A JP2022580236 A JP 2022580236A JP 2023532040 A5 JP2023532040 A5 JP 2023532040A5
Authority
JP
Japan
Prior art keywords
saponin
xyl
rha
fuc
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022580236A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023532040A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/NL2021/050384 external-priority patent/WO2021261992A1/en
Publication of JP2023532040A publication Critical patent/JP2023532040A/ja
Publication of JP2023532040A5 publication Critical patent/JP2023532040A5/ja
Pending legal-status Critical Current

Links

JP2022580236A 2020-06-24 2021-06-18 GalNAc及びサポニンのコンジュゲート、前記コンジュゲート及びGalNAc-オリゴヌクレオチドコンジュゲートを含む治療組成物 Pending JP2023532040A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
NL2025899 2020-06-24
NL2025899 2020-06-24
NL2026442 2020-09-10
NL2026442 2020-09-10
PCT/NL2021/050384 WO2021261992A1 (en) 2020-06-24 2021-06-18 Conjugate of galnac and saponin, therapeutic composition comprising said conjugate and a galnac-oligonucleotide conjugate

Publications (2)

Publication Number Publication Date
JP2023532040A JP2023532040A (ja) 2023-07-26
JP2023532040A5 true JP2023532040A5 (cg-RX-API-DMAC10.html) 2024-06-25

Family

ID=76584529

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022580236A Pending JP2023532040A (ja) 2020-06-24 2021-06-18 GalNAc及びサポニンのコンジュゲート、前記コンジュゲート及びGalNAc-オリゴヌクレオチドコンジュゲートを含む治療組成物

Country Status (10)

Country Link
US (1) US20230263897A1 (cg-RX-API-DMAC10.html)
EP (3) EP4171641B1 (cg-RX-API-DMAC10.html)
JP (1) JP2023532040A (cg-RX-API-DMAC10.html)
KR (1) KR20230043114A (cg-RX-API-DMAC10.html)
CN (2) CN116234582A (cg-RX-API-DMAC10.html)
AU (1) AU2026202914A1 (cg-RX-API-DMAC10.html)
ES (1) ES3002193T3 (cg-RX-API-DMAC10.html)
IL (1) IL299357A (cg-RX-API-DMAC10.html)
MX (1) MX2023000092A (cg-RX-API-DMAC10.html)
WO (1) WO2021261992A1 (cg-RX-API-DMAC10.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114072503A (zh) * 2019-07-02 2022-02-18 阿尔戈诺特Rna有限公司 载脂蛋白b拮抗剂
CN117355534B (zh) 2021-01-30 2026-05-01 唐格拉姆治疗公司 缀合寡核苷酸化合物、其制备方法和用途
WO2022162157A1 (en) * 2021-01-30 2022-08-04 E-Therapeutics Plc Conjugated oligonucleotide compounds, methods of making and uses thereof
CN115227700B (zh) * 2022-06-09 2024-03-19 大连医科大学 商陆皂苷甲在制备心肌梗死保护药物中的应用
JP2026519131A (ja) * 2023-06-02 2026-06-11 サプリーム テクノロジーズ,ベー.フェー. 細胞内分子標的を介して作用する治療エフェクター成分のための改善された治療レジメン
TW202504619A (zh) * 2023-07-20 2025-02-01 大陸商上海舶望製藥有限公司 用於抑制pd-l1表達的組合物和方法
CN116655715B (zh) * 2023-07-27 2023-10-20 北京炫景瑞医药科技有限公司 一种GalNAc衍生物、缀合物、组合物以及它们的用途
CN116854754B (zh) * 2023-09-01 2023-12-12 北京悦康科创医药科技股份有限公司 一种含有核糖环或其衍生结构的GalNAc化合物及其寡核苷酸缀合物
WO2025090612A1 (en) * 2023-10-27 2025-05-01 Wisconsin Alumni Research Foundation Lipid nanoparticles formed by lipidoids for efficient delivery of nucleotide drugs and biologics
WO2026087680A1 (en) 2024-10-24 2026-04-30 Sapreme Technologies B.V. Treatment for cardiovascular disease
WO2026087678A1 (en) 2024-10-24 2026-04-30 Sapreme Technologies B.V. Treatment for renal disorders
WO2026087695A1 (en) 2024-10-24 2026-04-30 Sapreme Technologies B.V. Treatment for metabolic disorder
WO2026119464A1 (en) 2024-12-03 2026-06-11 Sapreme Technologies B.V. Treatment for cns-related disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003275954A1 (en) * 2002-11-08 2004-06-07 Danmarks Fodevareforskning Preparation of chemically well-defined carbohydrate dendrimer conjugates
ES2395818T3 (es) * 2004-07-13 2013-02-15 Charite - Universitatsmedizin Berlin Composición que comprende un agente farmacológicamente activo acoplado a un componente específico de célula diana, y una saponina
WO2008007941A1 (en) * 2006-07-10 2008-01-17 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Gainac specific binding molecules and uses thereof
WO2011054811A1 (en) * 2009-11-03 2011-05-12 Santaris Pharma A/S Rna antagonists targeting hsp27 combination therapy
WO2011141703A1 (en) * 2010-05-12 2011-11-17 Protiva Biotherapeutics Inc. Compositions and methods for silencing apolipoprotein b
WO2011156751A2 (en) * 2010-06-11 2011-12-15 University Of Georgia Research Foundation, Inc. Immunogenic vaccine
US20150024037A1 (en) * 2012-02-16 2015-01-22 The University Of Toledo Xenoantigen-Displaying Anti-Cancer Vaccines and Method of Making
PL2992098T3 (pl) * 2013-05-01 2019-09-30 Ionis Pharmaceuticals, Inc. Kompozycje i sposoby modulowania ekspresji hbv i ttr
AR100516A1 (es) * 2014-05-19 2016-10-12 Pfizer Compuestos de 6,8-dioxabiciclo[3.2.1]octano-2,3-diol sustituidos como agentes de direccionamiento al asgpr
AU2015329974B2 (en) * 2014-10-10 2019-06-20 F. Hoffmann-La Roche Ag GaINAc phosphoramidites, nucleic acid conjugates thereof and their use
EP3514240A1 (en) * 2018-01-18 2019-07-24 Freie Universität Berlin Novel uses of a saponin and method for its isolation
US20220023433A1 (en) * 2018-12-21 2022-01-27 Sapreme Technologies B.V. Saponin Conjugates

Similar Documents

Publication Publication Date Title
JP7614094B2 (ja) 薬物コンジュゲート
EP4171641B1 (en) Conjugate of galnac and saponin, therapeutic composition comprising said conjugate and a galnac-oligonucleotide conjugate
US20240307545A1 (en) Conjugate of saponin, oligonucleotide and galnac
WO2022055351A1 (en) Conjugate of saponin, oligonucleotide and galnac
WO2022055352A1 (en) Semicarbazone-based saponin conjugate
AU2020454675B2 (en) Combination comprising an ADC or an AOC comprising a VHH, and a saponin or a ligand-saponin conjugate
JP2023532003A5 (cg-RX-API-DMAC10.html)
JP2023532679A5 (cg-RX-API-DMAC10.html)
US20230302140A1 (en) Conjugate of a single domain antibody, a saponin and an effector molecule, pharmaceutical composition comprising the same, therapeutic use of said pharmaceutical composition
JP2023532679A (ja) 抗体-薬物コンジュゲート及び抗体-サポニンコンジュゲートの組合せ
US20250295800A1 (en) Conjugate of a single domain antibody, a saponin and an effector molecule, pharmaceutical composition comprising the same, therapeutic use of said pharmaceutical composition
US20240327829A1 (en) Conjugate of saponin, oligonucleotide and galnac
KR20230043115A (ko) 히드라존에 기반한 사포닌 유도체
EP4210761B1 (en) Semicarbazone-based saponin conjugate
HK40132001A (en) Conjugate of a single domain antibody, a saponin and an effector molecule, pharmaceutical composition comprising the same, therapeutic use of said pharmaceutical composition
AU2021295358A1 (en) Conjugate of galnac and saponin, therapeutic composition comprising said conjugate and a galnac-oligonucleotide conjugate
HK40130827A (en) Combination comprising an adc or an aoc comprising a vhh, and a saponin or a ligand-saponin conjugate
NZ778372B2 (en) Biologically active cluster of molecules
HK40110483A (en) Conjugate of saponin, oligonucleotide and galnac
HK40110483B (en) Conjugate of saponin, oligonucleotide and galnac
AU2021339332A1 (en) Conjugate of saponin, oligonucleotide and GalNAc
HK40091234B (en) Conjugate of saponin, oligonucleotide and galnac
HK40091234A (en) Conjugate of saponin, oligonucleotide and galnac
Iacobelli Antibody-Drug Conjugates: The New Frontier of Chemotherapy